One Person's Trash Is Another Person's Treasure Selection: Dendreon

Three weeks ago, I announced my intention to create a portfolio composed of 10 companies that investors have unjustly cast aside. My goal in creating the One Person's Trash Is Another Person's Treasure portfolio is to highlight just how successful value investing and contrarian viewpoints can be, as well as uncover some great companies that have a good chance of turning their fortunes around. For a more thorough explanation of what I hope to accomplish and how I'll measure my success, I encourage you to visit my portfolio mission statement.

For reference, here are my previous two selections:

For my third selection, I've chosen biotechnology firm Dendreon (Nasdaq: DNDN  ) .

Why traders have given up on Dendreon
When Dendreon's late-stage prostate cancer treatment Provenge was approved by the Food and Drug Administration in April 2010, its prospects were immeasurable. With few treatments available to patients and what appeared to be a big survival advantage, Provenge was expected to become a blockbuster. However, a series of bungles -- including pricing the full course of treatment at $93,000 and marketing the drug on its own without a partner -- allowed its competition to sweep in and steal the show.

Currently, Johnson & Johnson's (NYSE: JNJ  ) Zytiga appears to be the metastatic castration-resistant prostate cancer treatment of choice among physicians, according to research firm Baird. Also, Medivation (Nasdaq: MDVN  ) and Astellas Pharma (NASDAQOTH: ALPMY  ) received an extremely rare early approval for Xtandi to treat prostate cancer in August. On top of this, you can add in competition from Jevtana, made by Sanofi (NYSE: SNY  ) . In Europe, Medivation has already filed for approval while Zytiga gained EU approval last year -- but only after dropping the price of Zytiga lower than its current $5,500 monthly bill that you find in the United States.

Simply put, the deck is already stacked against Dendreon, and it was forced to restructure its operations and reduce its workforce in order to cut expenses to manageable levels -- and still the company is losing money.

Why investors should trust Dendreon
Every basket portfolio of 10 companies should have one or two long-shot picks, and this is one of mine. Provenge sales may have limped out of the gate, and Dendreon's certainly moving at a snail's pace in Europe as it runs trials for EU regulators on safety, but there are plenty of ways Dendreon can turn things around.

To begin with, Dendreon could (and in my personal opinion, will) seek out a partner with more marketing knowledge, specifically abroad, which could then help Dendreon price its Provenge treatment to a level which is likely to draw the praise of EU regulators and insurers. As my Foolish colleague David Williamson recently noted, EU insurers are much more cost sensitive, so pricing Provenge appropriately in Europe will be important. Dendreon was recently informed by Aetna (NYSE: AET  ) that its Provenge treatment would be covered on a limited basis which may also spur more insurers domestically to cover the full treatment.

Secondly, don't discount the fact that Provenge is continuing to take market share from Zytiga -- it's just occurring at a slower pace than it had been occurring previously. Dendreon's latest quarter showed 27% product sales growth over the year-ago quarter even with sequential quarterly revenue falling 2.5%. With Dendreon's cost-saving restructuring expected to take full effect by the third-quarter of next year, we can expect losses and cash burn to minimize all while sales continue to inch higher.

A third point: Have we forgotten that Dendreon has an expansive pipeline? Currently, Dendreon is running five early and advanced phase 2 and phase 3 clinical trials with Sipuleucal-T (aka Provenge); an ongoing mid-stage trial for DN24-02, an active cellular immunotherapy that targets the HER2/neu receptor for the treatment of breast, ovarian, and colorectal solid tumors; and an early-stage trial for D3263-HCI, which targets and activates a specific type of calcium ion channel of the TRP protein series to cause cell death in solid tumors.

What you'd get here
As I said, this isn't going to be a typical One Person's Trash Is Another Person's Treasure selection, because I tend to focus on deep value discounts that have very low P/E ratios, often pay dividends, and have strong cash flow. That's not the case in any way, form, or shape with Dendreon.

Dendreon has lost money in each of the past 10 years, and its high R&D and marketing costs associated with its pipeline haven't made getting closer to profitability any easier. Yet, if you were to jump into Dendreon shares right now, you'd be paying just 1.8 times 2013 sales projections. Having followed the biotech sector for quite some time, I've learned that biotech investors are frequently willing to pay two to seven times peak sales of a drug perhaps a decade down the road. To me, this shows a large overreaction by pessimists to Provenge's potential at just 1.8 times next year's sales. In addition, you get a pipeline with eight current clinical candidates and multiple pre-clinical trials.

Assuming Dendreon gains approval to market Provenge in Europe, it wouldn't be out of the question to expect annual sales to boost over the $500 million mark within two years. It won't be an overnight success story, but I do believe Dendreon will prove the naysayers wrong in the end and that's why I'm adding it to the One Person's Trash Is Another Person's Treasure portfolio.

Is my bullishness misplaced? Get the answer to this question and much more by getting your copy of our latest premium research report on Dendreon. Packed with in-depth analysis on the opportunities and threats facing Dendreon -- and complete with a year of regular updates -- this report will give you the tools to make smart long-term investing decisions. Click here to learn more.


Read/Post Comments (1) | Recommend This Article (9)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On April 19, 2013, at 9:45 AM, adumfraudstain wrote:

    Yea but Zytiga data only shrinks tumors and does not extend survival. Provenge does.

    DNDN currently trades in $4's. Time to officially close out my Summer 2011 YMB DNDN Bear Raid Game from high $30's. Investors who listened made out like bandits.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2134409, ~/Articles/ArticleHandler.aspx, 9/16/2014 1:01:43 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 3 hours ago Sponsored by:
DOW 17,031.14 43.63 0.26%
S&P 500 1,984.13 -1.41 -0.07%
NASD 4,518.90 -48.70 -1.07%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/15/2014 3:59 PM
DNDN $1.52 Up +0.13 +9.35%
Dendreon Corp CAPS Rating: *
AET $82.12 Down -0.08 -0.10%
Aetna, Inc. CAPS Rating: ***
JNJ $104.72 Up +0.14 +0.13%
Johnson & Johnson CAPS Rating: ****
MDVN $93.27 Down -2.26 -2.37%
Medivation, Inc. CAPS Rating: **
SNY $56.11 Down -0.32 -0.57%
Sanofi (ADR) CAPS Rating: *****

Advertisement